Kamada KMDA
NASDAQ KMDA
$7.93 +0.04 (+0.51%)
At close: Aug 20, 2026 · 10:07 AM UTC

Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026)

Kamada's (KMDA) quarterly Net Income towards Common Stockholders came in at $6.6 million in Q1 2026, down 28.2% YoY from $9.3 million in Q1 2025, and up 12.6% on a QoQ basis from $5.9 million in Q4 2025.

Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends

Kamada (KMDA) has 15 years of Net Income towards Common Stockholders data on file, last reported at $6.6 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 28.2% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 38.82% YoY) and the FY2025 annual result came in at $26.7 million, up 119.04% from the prior year.
  • Net Income towards Common Stockholders grew to $6.6 million in Q1 2026, from $5.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $9.3 million in Q1 2025 to a low of -$1809.0 in Q1 2023.
  • A 5-year average of $3.3 million and a median of $3.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • The widest YoY moves for Net Income towards Common Stockholders: up 537066.67% in 2023, down 100.1% in 2023.
  • Tracing KMDA's Net Income towards Common Stockholders over 5 years: stood at $3.2 million in 2022, then surged by 53.68% to $5.0 million in 2023, then sank by 77.76% to $1.1 million in 2024, then surged by 432.07% to $5.9 million in 2025, then advanced by 12.6% to $6.6 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at $6.6 million (Q1 2026), $5.9 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 43.60 Bn 42.64 Bn - -
2 Teva Pharmaceutical Industries 43.15 Bn 39.50 Bn 2.15 Bn -576.00 Mn
3 Zoetis 31.41 Bn 29.73 Bn 1.05 Bn 866.00 Mn
4 Takeda Pharmaceutical 28.66 Bn 22.86 Bn 5.10 Bn 710.19 Mn
5 United Therapeutics 22.22 Bn 19.55 Bn 683.80 Mn 333.00 Mn
6 Viatris 18.77 Bn 17.88 Bn 1.46 Bn -118.80 Mn
7 Neurocrine Biosciences 15.69 Bn 15.30 Bn 935.80 Mn 144.40 Mn
8 Elanco Animal Health 12.06 Bn 11.53 Bn 798.00 Mn 54.00 Mn
9 Dr Reddys Laboratories 10.07 Bn 9.91 Bn - -
10 Kamada 457.14 Mn 427.66 Mn 22.47 Mn 9.26 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 9.26 Mn
Mar 31, 2026 6.65 Mn
Dec 31, 2025 5.91 Mn
Sep 30, 2025 7.44 Mn
Jun 30, 2025 6,328.00
Mar 31, 2025 9.26 Mn
Dec 31, 2024 1.11 Mn
Sep 30, 2024 4.03 Mn
Jun 30, 2024 4,552.00
Mar 31, 2024 2.51 Mn
Dec 31, 2023 4.99 Mn
Sep 30, 2023 3.22 Mn
Jun 30, 2023 1.81 Mn
Mar 31, 2023 -1,809.00
Dec 31, 2022 3.25 Mn
Sep 30, 2022 600.00
Jun 30, 2022 3.95 Mn
Mar 31, 2022 1.83 Mn
Dec 31, 2021 -4.82 Mn
Sep 30, 2021 868,000.00